Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE still down on overall survival benefit of Roche's Herceptin and GSK's Tyverb following appeal

This article was originally published in Scrip

Executive Summary

NICE, the health technology appraisal body for England and Wales, is still not convinced that either GSK's Tyverb (lapatinib) or Roche's Herceptin (trastuzumab) offer substantial enough overall survival benefit to be recommended as a first-line treatment for some breast cancer patients whose cancer overexpresses HER2. Today's new appraisal consultation document comes after NICE had to rethink previous final draft recommendations in the wake of an appeal from Roche.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts